Gathering the record
Relay is organizing the evidence and source boundaries.
Unimolecular GLP-1 / amylin receptor co-agonist
An experimental weight-loss drug, previously called amycretin. Injection and tablet versions are being studied separately.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Peer-reviewed randomized 36-week subcutaneous early-phase obesity evidence and a 448-participant Phase 2 diabetes program reported by the sponsor.
It is not the same as co-injecting two separate products.
The highest exploratory arm reached 24.3%.
Sponsor reporting showed larger effects with the leading subcutaneous regimens.
Upper subcutaneous arms had substantial discontinuation and gastrointestinal events; dysesthesia was also reported.
Pivotal registration is not proof of benefit.
Risks & unknowns
High-dose tolerability is a material uncertainty.
Other human evidenceRates and dose relationships require fuller publication and Phase 3 confirmation.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Relay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational — Phase 2 results; Phase 3 initiated Phase 3 efficacy and tolerability, dose optimization, high-dose discontinuation, dysesthesia, oral-versus-injectable durability, rare events, and cardiovascular outcomes.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
The Phase 1b/2a trial studied weekly injections in adults with overweight or obesity. Oral amycretin is a separate formulation.
| Maintenance-target cohort | Target | Total treatment period |
|---|---|---|
| C | 1.25 mg | 20 weeks |
| D | 5 mg | 28 weeks |
| E | 20 mg | 36 weeks |
Each listed cohort included 12 weeks at its maintenance target. A separate exploratory arm escalated to 60 mg; that is not the target for every group. Exact intermediate steps are not provided here.
Amycretin · Phase 1b/2a subcutaneous trial Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A peer-reviewed early-phase trial investigated the injectable form in adults with overweight or obesity, focusing on weight change, safety, and tolerability.
Population: Adults with overweight or obesity
Design: Randomized, placebo-controlled multiple-dose trial
Mechanisms
Zenagamtide is a unimolecular co-agonist of GLP-1 and amylin receptors developed in subcutaneous and oral formulations. A peer-reviewed Phase 1b/2a obesity study reported dose-dependent weight reduction, reaching 24.3% at 36 weeks in the highest exploratory subcutaneous arm. In a 448-participant Phase 2 type 2 diabetes trial, Novo Nordisk reported subcutaneous weight reduction up to 14.6% and oral reduction up to 10.1% at 36 weeks, with HbA1c reductions around 1.7–1.8 percentage points in leading subcutaneous arms. Gastrointestinal events were common, and discontinuation was high in the upper subcutaneous dose groups. Phase 3 programs are underway, but no approved indication exists.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Published subcutaneous evidence, Phase 2 oral and injectable research, and Phase 3.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Strong measured signals coexist with high-dose discontinuation uncertainty.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The dose groups were small and exploratory despite the 36-week observation period. The findings do not establish Phase 3 benefit, an approved product, or equivalence between injectable and oral formulations. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, placebo-controlled multiple-dose trial
Adults with overweight or obesity
Weight reduction was dose dependent and reached 24.3% in the highest exploratory arm at 36 weeks.
Study administration: Once-weekly subcutaneous amycretin dose-escalation regimens or placebo
Limitations: Small dose cohorts and an exploratory early-phase design limit generalization.
Randomized pivotal obesity trial
Adults with obesity or overweight
Phase 3 is evaluating longer-term efficacy and tolerability.
Study administration: Zenagamtide or comparator
Limitations: No Phase 3 outcomes were available.
Randomized, placebo-controlled subcutaneous and oral dose-ranging trial
Adults with type 2 diabetes
The sponsor reported subcutaneous weight reduction up to 14.6% and oral reduction up to 10.1%, with substantial HbA1c improvement.
Study administration: Weekly subcutaneous or daily oral zenagamtide dose groups or placebo
Limitations: Conference and investor materials are less complete than a peer-reviewed full paper.
Official registry record for the diabetes trial
Adults with type 2 diabetes
The registry confirms the mixed-route Phase 2 design.
Study administration: Subcutaneous or oral amycretin versus placebo
Limitations: Registry information does not independently confirm sponsor-reported effect sizes.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-06-01
2026-04-01 · NCT07668414
2025-06-01 · PMID 40550231
2024-08-01 · NCT06542874